相关实验视频

Updated: Jul 11, 2025

Using Retinal Imaging to Study Dementia

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

在阿尔茨海默病中潜在的视网膜生物标志物

Mariana Yolotzin García-Bermúdez¹, Rupali Vohra^1,2, Kristine Freude³

¹Eye Translational Research Unit, Department of Drug Design and Pharmacology, University of Copenhagen, 2100 Copenhagen, Denmark.

International journal of molecular sciences

|November 14, 2023

概括

诊断阿尔茨海默病 (AD) 是一个挑战,但视网膜生物标志物为早期检测提供了一个有希望的,非侵入性的方法. 研究正在探索这些眼睛的变化,以克服诊断障碍并识别AD特异性标记物.

科学领域:

眼科医生眼科眼科
神经学神经学
生物标志物发现发现

背景情况:

阿尔茨海默病 (AD) 诊断仍然是一个重大挑战,需要早期检测才能有效治疗.
目前用于AD的诊断方法面临局限性,影响及时干预.
人们越来越认识到视网膜是大脑的一个潜在的非侵入性窗口,用于检测神经系统的变化.

研究的目的:

审查当前阿尔茨海默病 (AD) 评估中的诊断挑战.
探索视网膜变化的潜力,作为阿尔茨海默病的早期指标.
突出识别视网膜生物标志物的重要性,以早期诊断AD.

主要方法:

对AD诊断和视网膜成像研究的综合文献综述.
对用于神经退行性疾病的视网膜生物标志物的研究进行分析.
检查区分AD特异性视网膜变化与其他视网膜疾病的挑战.

主要成果:

视网膜为早期AD检测提供了一个可行的,非侵入性的途径.
与AD相关的视网膜变化和其他视网膜疾病之间的相似性使特定生物标志物的识别变得复杂.
在了解阿尔茨海默病中视网膜改变方面取得了重大进展.

结论:

视网膜检查对早期诊断阿尔茨海默病有相当大的前景.
克服诊断挑战需要确定与AD相关的特定视网膜生物标志物.
进一步的研究对于推进视网膜分析在阿尔茨海默病诊断中的应用至关重要.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.代谢过程中的代谢.线粒体中的线粒体.眼睛生物标志物眼睛生物标志物视网膜的改变视网膜的改变

更多相关视频

In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma

In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma

Published on: May 11, 2015

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...